Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (620)	1/27/2005 1:36:44 PM
From: richardred	Read Replies (1) \| Respond to of 7242

I clearly expect Dansico to sell off GCOR assets that don't fit, to cut down on it's purchase price. Clearly a good deal for Dansico based on EBITDA now and going forward. This in light of Dansico jettisoning money loosing drug research efforts. Revenue (ttm): 403.16M Revenue Per Share (ttm): 6.579 Revenue Growth (lfy)³: 9.50% Gross Profit (ttm)²: 175.68M EBITDA (ttm): 48.15M Net Income Avl to Common (ttm): 27.20M Diluted EPS (ttm): 0.446 Earnings Growth (lfy)³: 293.40% Balance Sheet Total Cash (mrq): 167.66M Total Cash Per Share (mrq): 2.81 Total Debt (mrq)²: 62.62M Total Debt/Equity (mrq): 0.115 Current Ratio (mrq): 3.569 Book Value Per Share (mrq): 6.074